Loading...
•
Sep 30, 2022
SpringWorks Therapeutics Q3 2022 Earnings Report
Reported third quarter financial results and provided an update on recent company developments.
Key Takeaways
SpringWorks Therapeutics presented positive data from its Phase 3 DeFi trial of nirogacestat, expanded collaboration with GSK, and initiated a new Phase 2 trial of nirogacestat. They also strengthened their financial position, providing sufficient runway into 2026.
Presented positive data from Phase 3 DeFi trial of nirogacestat in patients with desmoid tumors at ESMO Congress 2022.
Expanded global, non-exclusive collaboration with GSK to continue evaluating nirogacestat in combination with belantamab mafodotin in patients with multiple myeloma.
Dosed first patient in Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors.
Strengthened financial position to over $650 million in cash, cash equivalents and marketable securities.
Forward Guidance
This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...